{"id":"NCT00751881","sponsor":"Sanofi","briefTitle":"An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis","officialTitle":"A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2012-04","completion":"2015-08","firstPosted":"2008-09-12","resultsPosted":"2013-06-26","lastUpdate":"2016-07-07"},"enrollment":1169,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Teriflunomide","otherNames":["HMR1726"]}],"arms":[{"label":"Teriflunomide 7 mg / 14 mg","type":"EXPERIMENTAL"},{"label":"Teriflunomide 14 mg / 14 mg","type":"EXPERIMENTAL"},{"label":"Placebo / Teriflunomide 14 mg","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS.\n\nKey secondary objective was to assess the effect of the two doses of teriflunomide, in comparison to placebo, on disability progression.\n\nOther secondary objectives were:\n\n* To assess the effect of the two doses of teriflunomide in comparison to placebo on:\n\n  * Fatigue;\n  * Health-related quality of life, a measure of the impact of the participant's health on his or her overall well being.\n* To evaluate the safety and tolerability of teriflunomide.","primaryOutcome":{"measure":"Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate","timeFrame":"Core treatment period between 48 - 152 weeks depending on time of enrollment","effectByArm":[{"arm":"Placebo","deltaMin":0.501,"sd":null},{"arm":"Teriflunomide 7 mg","deltaMin":0.389,"sd":null},{"arm":"Teriflunomide 14 mg","deltaMin":0.319,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0001"},{"comp":"OG000 vs OG001","p":"0.0183"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":193,"countries":["United States","Australia","Austria","Belarus","Belgium","Canada","Chile","China","Czechia","Estonia","France","Germany","Greece","Mexico","Netherlands","Philippines","Poland","Romania","Slovakia","Spain","Sweden","Thailand","Tunisia","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["24461574","33023488","32911306","30511679","29796289","28304217"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":385},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Alanine aminotransferase increased","Alopecia"]}}